| Background:Ovarian cancer is one of the most common malignancy of the prevalent gynecologic cancers in women and can attack in each age group. Epithelial ovarian tumors occur in women after the age of 50 and the 5-year survival rate has been hovering at 30%-40%. The mortality ranks first in gynecological malignancies so that it has become a major serious threat to women’s life and health. Serous ovarian cancer accounts for 75% of epithelial ovarian cancer and the 5-year survival rate was 30.6%. There is a lack of simple and practical diagnostic method which is highly specific and sensitive. More than 70% of the patients have been advanced stage when they visit. So early screening,early detection,early diagnosis,early treatment is the key to improve survival in patients with ovarian cancer. Human leukocyte antigen-E (HLA-E) is a non-classical HLA I molecules. Many studies have shown that it take part in tumor immune escape, which is highly expressed in tumor tissues and in blood of cancer patients. The report about HLA-E expression in serous ovarian cancer is rare. So we detection HLA-E in serous ovarian cancer by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) method and we study its role in the pathogenesis of serous ovarian cancer to search for a new diagnostic target.Objective:To detect the expression of HLA-E in the tissue or the solube HLA-E in the serum of patients with serous ovarian cancers compared with normal controls, to explore its effect and significance in the development of serous ovarian cancer and to discuss its possible clinical application in the diagnosis of serous ovarian cancer compared with CA125.Methods:48 serous ovarian cancer specimens are collected from the pathology department of Shandong Provincial Hospital from July 2012 to September 2015. Their ages rang from 26 to 72 years old. According to FIGO stage, it include 18 cases of early stage (I stage, Ⅱ stage), and 30cases of advanced stage (III stage, IV stage).12 cases of benign ovarian tumor are the control group.42 blood samples of ovarian tumor and uterine fibroids patients were collected from July 2015 to November 2015 who were treated in Shandong Provincial Hospital gynecological, including 30 cases of serous ovarian cancer and 12 patients with benign tumors (control group).1. Immunohistochemistry method was used to detect the expression of HLA-E in 48 cases of serous ovarian cancer tissues and 12 cases of benign ovarian tissues, and its relationship to clinical pathological characteristics of serous ovarian cancer was also analyzed.2. ELISA was used to detect plasma of 30 ovarian cancer and 12 normal controls, compare the differences among them and analyze its possible role in tumor formation.3.Using ROC curve to analyze the early-stage diagnosis values of sHLA-E and CA125, respectively. Compared all results, to evaluate the possible diagnosis values of sHLA-E in lesions before formation of serous ovarian cancer.Result:1.The positive expression rate of HLA-E in serous ovarian cancer (72.92%,35/48)was higher than that in benign ovarian tissues (8.3%,1/12) (P<0.05). The positive expression rate of HLA-E was closely related with clinical stage,but,no relation with age and differentiation degree.2. Soluble HLA-E level in the serous ovarian cancer group (767.03±202.19ng/mL)were significantly higher than normal controls (616.06±86.39ng/mL)3.Analysis of ROC curve demonstrated that sHLA-E had significantly superior performance to CA125. The cutoff of sHLA-E was 631.90 ng/mL and the sensitivity and specificity was 75% and75%,respectively.Conclusion:1.Expression of HLA-E in serous ovarian tumors are significantly higher than that in normal tissues, and HLA-E also play an important role in the development of ovarian cancer.2.Compared with CA125,sHLA-E has ascendancy in the diagnosis of early-stage in ovarian cancer, and may be investigated further for clinical application. |
PDF Full Text Request